Log in

Start Your Membership Now

French pharmaceutical organization Servier and biotechnology organization Neurochlore recently announced they are launching phase 3 studies to evaluate the use of Bumetanide in children with autism spectrum disorder (ASD). Bumetanide is classically used to treat fluid retention (edema) and high blood pressure.

The plan for the two six-month studies was recently approved by the Pediatric Committee of the European Medicines Agency, and will monitor the children having Bumetanide administered to them twice daily to evaluate its efficacy and safety in alleviating ASD symptoms. The evaluation will particularly focus on the children's performance with social communication and interaction, as . . .

Want To Read More? Log In Or Become A Free Member
Resource Available For All OPEN MINDS Circle Members
Log In
If you are already a member, log in to your account to access this resource and more.

Become A Free Member
You can become a free member and get access now. Learn more about the OPEN MINDS Circle Market Intelligence Service Membership. Reach out to our team at info@openminds.com, or call us at 877-350-6463.

A Paid OPEN MINDS Circle Membership provides unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!

Service & Treatment Updates

Categories
All Bulletins
Submit a Bulletin
  • This field is for validation purposes and should be left unchanged.
  • Max. file size: 98 MB.